Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase NA 1Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neurotoxicity Syndromes 1Lymphoma 1Central Nervous System Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × motexafin gadolinium × Clear all
NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡